Literature DB >> 16624496

A nutritional supplement formula for influenza A (H5N1) infection in humans.

Howard Friel1, Harvey Lederman.   

Abstract

By early February 2006, the World Health Organization had reported 165 human cases of H5N1 influenza since December 2003, with 88 fatalities. However, the avian H5N1 influenza virus apparently is not yet efficiently transmitted between humans. Though a near-term possibility of a global H5N1 influenza pandemic remains, currently there is no vaccine or anti-viral drug that is proven to be safe and effective in preventing or treating H5N1 influenza in humans. There is thus a compelling public interest in developing alternative prophylaxis and treatment strategies for H5N1 influenza, which would need to address the complex pathogenesis of H5N1 influenza that is responsible for its apparently unusually high virulence. The authors present here a significant body of medical and scientific evidence to support the prophylactic use of a carefully designed nutritional supplement formulation that may antagonize the major pathogenic processes of H5N1 influenza in humans. Through several independently-mediated mechanisms, the formulations may: (a) degrade H5N1 virulence by directly affecting the virus itself, (b) inhibit H5N1 viral replication by maintaining cellular redox equilibrium in host cells, (c) inhibit H5N1 replication by a blockade of the nuclear-cytoplasmic translocation of the viral ribonucleoproteins and reduced expression of late viral proteins related to the inhibition of protein kinase C activity and its dependent pathways, (d) down-regulate activation and proliferation of proinflammatory cytokines in respiratory epithelial cells and macrophages that are implicated in the pathogenesis of H5N1 influenza, and (e) protect the lungs and other vital organs from virus- and cytokine-induced oxidative stress by supplying and maintaining sufficient levels of exogenous and endogenous antioxidants. Key mediators in these processes include selenium, vitamin E, NAC/glutathione, resveratrol, and quercetin. Taken prophylactically, and throughout the duration and recovery of an H5N1 infection, the nutritional supplement formula may aid humans infected with H5N1 influenza to survive with a reduced likelihood of major complications, and may provide a relatively low-cost strategy for individuals as well as government, public-health, medical, health-insurance, and corporate organizations to prepare more prudently for an H5N1 pandemic. Some evidence also indicates that the supplement formulation may be effective as an adjunctive to H5N1 vaccine and anti-viral treatments, and should be tested as such.

Entities:  

Mesh:

Year:  2006        PMID: 16624496     DOI: 10.1016/j.mehy.2006.02.040

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  9 in total

Review 1.  Intracellular redox state as target for anti-influenza therapy: are antioxidants always effective?

Authors:  Rossella Sgarbanti; Donatella Amatore; Ignacio Celestino; Maria Elena Marcocci; Alessandra Fraternale; Maria Rosa Ciriolo; Mauro Magnani; Raffaele Saladino; Enrico Garaci; Anna Teresa Palamara; Lucia Nencioni
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

Review 2.  Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus.

Authors:  R Gasparini; D Amicizia; P L Lai; N L Bragazzi; D Panatto
Journal:  J Prev Med Hyg       Date:  2014-12

Review 3.  Exercise in Glucose-6-Phosphate Dehydrogenase Deficiency: Harmful or Harmless? A Narrative Review.

Authors:  Kalliopi Georgakouli; Ioannis G Fatouros; Dimitrios Draganidis; Konstantinos Papanikolaou; Panagiotis Tsimeas; Chariklia K Deli; Athanasios Z Jamurtas
Journal:  Oxid Med Cell Longev       Date:  2019-04-04       Impact factor: 6.543

Review 4.  Metabolic host response and therapeutic approaches to influenza infection.

Authors:  Mohsen Keshavarz; Farid Solaymani-Mohammadi; Haideh Namdari; Yaser Arjeini; Mohammad Javad Mousavi; Farhad Rezaei
Journal:  Cell Mol Biol Lett       Date:  2020-03-05       Impact factor: 5.787

5.  Clinical management of pandemic 2009 influenza A(H1N1) infection.

Authors:  David S Hui; Nelson Lee; Paul K S Chan
Journal:  Chest       Date:  2009-12-18       Impact factor: 9.410

Review 6.  Glutathione: new roles in redox signaling for an old antioxidant.

Authors:  Katia Aquilano; Sara Baldelli; Maria R Ciriolo
Journal:  Front Pharmacol       Date:  2014-08-26       Impact factor: 5.810

7.  Screening of melatonin, α-tocopherol, folic acid, acetyl-L-carnitine and resveratrol for anti-dengue 2 virus activity.

Authors:  Atchara Paemanee; Atitaya Hitakarun; Sittiruk Roytrakul; Duncan R Smith
Journal:  BMC Res Notes       Date:  2018-05-16

Review 8.  Redox control in the pathophysiology of influenza virus infection.

Authors:  Ker-Kong Chen; Moeko Minakuchi; Kenly Wuputra; Chia-Chen Ku; Jia-Bin Pan; Kung-Kai Kuo; Ying-Chu Lin; Shigeo Saito; Chang-Shen Lin; Kazunari K Yokoyama
Journal:  BMC Microbiol       Date:  2020-07-20       Impact factor: 4.465

9.  Glucose-6-phosphate dehydrogenase deficiency enhances human coronavirus 229E infection.

Authors:  Yi-Hsuan Wu; Ching-Ping Tseng; Mei-Ling Cheng; Hung-Yao Ho; Shin-Ru Shih; Daniel Tsun-Yee Chiu
Journal:  J Infect Dis       Date:  2008-03-15       Impact factor: 5.226

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.